Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mack N Barnes

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Gynecologic Oncology|January 15, 2008
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group studyAngeles Alvarez Secord, John A Blessing, Deborah K Armstrong, et al.
Gynecologic Oncology|February 21, 2006
Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancerJacob M Estes, Charles A Leath, Sybilann Williams, et al.
Gynecologic Oncology|September 24, 2004
The impact of aborted radical hysterectomy in patients with cervical carcinomaCharles A Leath, J Michael Straughn, Jacob M Estes, et al.
The Oncologist|April 15, 2006
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patientsRodney P Rocconi, J Michael Straughn, Charles A Leath, et al.
Disease Markers|February 6, 2004
p53 and erbB-2 are not associated in matched cases of primary and metastatic ovarian carcinomasCristina Rodríguez-Burford, David C Chhieng, Cecil R Stockard, et al.
Gynecologic Oncology|December 7, 2002
A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesisMack N Barnes, Wallace D Berry, J Michael J Straughn, et al.
Journal of the National Cancer Institute|May 16, 2002
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirusAkseli Hemminki, Kurt R Zinn, Bin Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2011
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group studyCarol Aghajanian, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|August 12, 2008
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinomaKristopher J Kimball, T Michael Numnum, Tyler O Kirby, et al.
Gynecologic Oncology|October 19, 2006
A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapyWhitney A Spannuth, Charles A Leath, Warner K Huh, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Gynecologic Oncology|January 15, 2008
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group studyAngeles Alvarez Secord, John A Blessing, Deborah K Armstrong, et al.
Gynecologic Oncology|February 21, 2006
Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancerJacob M Estes, Charles A Leath, Sybilann Williams, et al.
Gynecologic Oncology|September 24, 2004
The impact of aborted radical hysterectomy in patients with cervical carcinomaCharles A Leath, J Michael Straughn, Jacob M Estes, et al.
The Oncologist|April 15, 2006
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patientsRodney P Rocconi, J Michael Straughn, Charles A Leath, et al.
Disease Markers|February 6, 2004
p53 and erbB-2 are not associated in matched cases of primary and metastatic ovarian carcinomasCristina Rodríguez-Burford, David C Chhieng, Cecil R Stockard, et al.
Gynecologic Oncology|December 7, 2002
A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesisMack N Barnes, Wallace D Berry, J Michael J Straughn, et al.
Journal of the National Cancer Institute|May 16, 2002
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirusAkseli Hemminki, Kurt R Zinn, Bin Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2011
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group studyCarol Aghajanian, Michael W Sill, Kathleen M Darcy, et al.
Gynecologic Oncology|August 12, 2008
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinomaKristopher J Kimball, T Michael Numnum, Tyler O Kirby, et al.
Gynecologic Oncology|October 19, 2006
A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapyWhitney A Spannuth, Charles A Leath, Warner K Huh, et al.
Pageof 5